Industry News

November 30, 2017 
Joint Statement to FDA Regarding Bacterial Risk Control Strategies


September 14, 2017
Outbreak of disease carried by mosquitoes halts blood donation in Rome 


August 26, 2016
Revised FDA Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components


August 25, 2016
Mediware® Releases LifeTrak® 2015 Module for Blood Establishments to Include Management of Pathogen Reduction Technology Data


July 28, 2016
FDA Advice to Blood Collection Establishments on Non-Travel Related Cases of Zika Virus in Florida


July 6, 2016
Unintended Consequence: Blood Banks Could Feel The Squeeze From Zika Advisories

June 14, 2016 
Newsweek – Will the FDA’s Policy on Blood Donation From Gay Men Change After the Orlando Massacre?


March 14, 2016
Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry
FDA recommendations for controlling the risk of bacterial contamination of platelets


February 16, 2016
Recommendations for Donor Screening, Deferral, and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus; Guidance for Industry
FDA blood safety guidance for areas of active and non-active transmission of Zika virus


November 17, 2015
Dallas Morning News - Hidden Threat: The Kissing Bug
Part 2: A Fatal Flow - Blood supply system lacks key safeguards against dreaded Chagas disease


May 14, 2015
New England Journal of Medicine – The Safety of the Blood Supply — Time to Raise the Bar
Authors from Yale University and the American Red Cross encourage the FDA to mandate the treatment of blood components with pathogen reduction technology.


November 24, 2014
WIRED – Feds Stockpiling Ebola Survivors’ Plasma to Treat Future Patients
Cerus’ INTERCEPT Blood System to be used by Emory Hospital


November 18, 2014
Gates Foundation Announces Support to Ebola-Affected Countries To Accelerate the Evaluation of Potential Treatments
Cerus provides support for convalescent plasma through the use of the INTERCEPT Blood System



Any links to third party Web pages from this Web site are provided for your convenience only. Cerus does not monitor, author, edit, or endorse any information provided in these third party pages and assumes no responsibility for the accuracy of their content.

  • Global Headquarters

  • 2550 Stanwell Drive
    Concord, CA US 94520
    +1 925.288.6000
  • European Headquarters

  • Stationsstraat 79-D
    3811 MH Amersfoort, Netherlands
    +31 (0) 33 49 60 600